Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332741 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL16386595 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL6569985 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL16386591 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL5703634 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL28916787 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL6921290 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL3731170 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL6879505 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL11668066 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116349679-A | Composite disinfection and sterilization method | 孙国明 | 2023-06-30 | — | — | CN | claimed |
| US-12150996-B2 | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-11-26 | — | — | US | disclosed |
| US-20240043369-A1 | CROSSLINKING COMPOUNDS AND CROSSLINKED ACRYLIC POLYMERIC MATERIALS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-02-08 | — | — | US | disclosed |
| CN-111615405-B | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | 国家科学研究中心 | 2023-11-28 | — | — | CN | disclosed |
| CN-116349679-A | Composite disinfection and sterilization method | 孙国明 | 2023-06-30 | — | — | CN | disclosed |
| CN-115433376-A | Preparation method of long-acting disinfection and sterilization fabric or fiber | 孙国明 | 2022-12-06 | — | — | CN | disclosed |
| US-20200353090-A1 | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | Universite Paris-Saclay (FR) | 2020-11-12 | — | — | US | disclosed |
| CN-111615405-A | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | 国家科学研究中心 | 2020-09-01 | — | — | CN | disclosed |
| EP-2521711-B1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-08-16 | — | — | EP | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084849-A1 | DIARYLDIAZEPINE PRODRUGS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20060167096-A1 | Livestock products with an increased ppar/rxr heterodimer activator level | INVE TECHNOLOGIES NV (BE) | 2006-07-27 | — | — | US | disclosed |
| EP-1638410-A1 | LIVESTOCK PRODUCTS WITH AN INCREASED PPAR/RXR HETERODIMER ACTIVATOR LEVEL | International Engineering and Trading, afgekort I.E.T. (BE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000036-A1 | LIVESTOCK PRODUCTS WITH AN INCREASED PPAR/RXR HETERODIMER ACTIVATOR LEVEL | INTERNATIONAL ENGINEERING AND TRADING, AFGEKORT I.E.T. (BE) | 2005-01-06 | — | — | WO | disclosed |
| CN-1108796-C | Use of anticancer material and production method of said anti-cancer material | YANG ZHENHUA (CN) | 2003-05-21 | — | — | CN | disclosed |
| CN-1251296-A | Use of anticancer material and production method of said anti-cancer material | YANG ZHENHUA (CN) | 2000-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12150996-B2 | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | IDE, SI, PYGM | CYP4F2 1362/4885CYP4A11 547/4885MAPT 2718/4885 |
| US-20200353090-A1 | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | IDE, SI, PYGM | CYP4F2 1347/4885CYP4A11 549/4885MAPT 2737/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | CYP4F2 2028/4885CYP4A11 571/4885MAPT 1129/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | CYP4F2 173/4885CYP4A11 749/4885MAPT 349/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | CYP4F2 125/4885CYP4A11 69/4885MAPT 363/4885 |
| US-20240043369-A1 | CROSSLINKING COMPOUNDS AND CROSSLINKED ACRYLIC POLYMERIC MATERIALS | LIG3, AAAS, DCLRE1A | CYP4F2 4017/4885CYP4A11 4607/4885MAPT 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.